MARKET

SLS

SLS

Sellas Life Sciences Group Inc
NASDAQ
13.96
+0.10
+0.72%
Pre Market: 14.11 +0.15 +1.06% 05:21 09/09 EDT
OPEN
13.77
PREV CLOSE
13.86
HIGH
14.37
LOW
13.32
VOLUME
632
TURNOVER
0
52 WEEK HIGH
15.88
52 WEEK LOW
1.390
MARKET CAP
2.82B
P/E (TTM)
-64.5102
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at SLS last week (0831-0904)?
Weekly Report · 2d ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS
Barchart · 6d ago
Most shorted stocks on Wall Street
Seeking Alpha · 6d ago
Most and least shorted mid- to mega-cap healthcare stocks at the end of August
Seeking Alpha · 6d ago
SELLAS Life Sciences Says Three Abstracts Evaluating SLS009, Potent, Selective CDK9 Inhibitor, In Preclinical Models Of PDAC Accepted For Poster Presentation At AACR Conference On Pancreatic Cancer
Benzinga · 6d ago
Why Analysts Think Sellas Life Sciences Stock Can Gain 150% From Here
Barchart · 09/01 09:52
Weekly Report: what happened at SLS last week (0824-0828)?
Weekly Report · 08/31 09:29
Frank Gerola's BMF Targets SELLAS Life Sciences $3 Billion Valuation: Biotech's 'Most Expensive Coin Flip'
Benzinga · 08/31 06:47
More
About SLS
SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the development of therapeutics for a range of cancer indications. The Company's product candidates are galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor. GPS is a cancer immunotherapeutic agent licensed by Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is developing SLS009, which is licensed by GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of mainland China, Hong Kong, Macau, and Taiwan.

Webull offers Sellas Life Sciences Group Inc stock information, including NASDAQ: SLS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SLS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SLS stock methods without spending real money on the virtual paper trading platform.